3-甲氧基-4-丙氧基苯乙胺 | 86456-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲氧基-4-丙氧基苯乙胺
• 英文名称: 2-(3-methoxy-4-propoxyphenyl)ethan-1-amine
• 英文别名: 2-(3-Methoxy-4-propoxyphenyl)ethanamine
• CAS: 86456-98-6
• 化学式: C₁₂H₁₉NO₂
• 分子量: 209.288
• InChiKey: SREDMHHCBHOIIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲氧基-4-丙氧基苯乙胺 在 PPA 、 Polyphosphoric acid (PPA) 作用下， 反应 9.0h， 生成 6-Methoxy-7-propoxy-3,4-dihydroisoquinoline
  参考文献：
  名称：

  Synthesis and antihypertensive activity of a series of spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one]s

  摘要：

  The 2R*,11bS* and 2S*,11bS* diastereoisomers of the spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2, 5'-oxazolidin-2'-one] system were prepared by stereoselective methods. Evaluation of these compounds for antihypertensive activity by oral administration to the spontaneously hypertensive rat showed the 2S*,11bS* series was the more potent. Within that series it was found that small alkyl substituents at positions 3 and 4' enhanced antihypertensive activity and that methoxyl substitution at positions 9 and 10 was optimal. (2S,3S,11bS)-Spiro-[2-ethyl-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one] [(-)-9e] was one of the most efficacious compounds of this series, while its antipode, (+)-9e, was inactive. Selected compounds in this series were shown to be alpha-adrenoceptor antagonists.

  DOI：

  10.1021/jm00364a013

文献信息

• Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
  申请人：Liu Haiyan

  公开号：US20110009628A1

  公开（公告）日：2011-01-13

  The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

  目前的技术涉及到公式I-VI的化合物以及制备和使用这些化合物的方法。使用方法包括预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。本文披露的化合物还可以增加高密度脂蛋白胆固醇（HDL-C），降低总胆固醇、低密度脂蛋白胆固醇（LDL-C）和甘油三酯，并增加肝LDL受体表达，抑制PCSK9表达，并激活AMP激活蛋白激酶。
• Discovery of Aporphine Analogues as Potential Antiplatelet and Antioxidant Agents: Design, Synthesis, Structure-Activity Relationships, Biological Evaluations, and in silico Molecular Docking Studies
  作者：Vashundhra Sharma、Pradeep K. Jaiswal、Surendra Kumar、Manas Mathur、Ajit K. Swami、Dharmendra K. Yadav、Sandeep Chaudhary

  DOI：10.1002/cmdc.201800318

  日期：2018.9.6

  e,g]quinoline, 2‐ethoxy‐1,9,10‐trimethoxy‐6‐(methylsulfonyl)‐5,6,6a,7‐tetrahydro‐4H‐dibenzo[de,g]quinoline, 1‐ethoxy‐2,9,10‐trimethoxy‐6‐(methylsulfonyl)‐5,6,6a,7‐tetrahydro‐4H‐dibenzo[de,g]quinoline, 2,9,10‐trimethoxy‐6‐(methylsulfonyl)‐1‐propoxy‐5,6,6a,7‐tetrahydro‐4H‐dibenzo[de,g]quinoline, and 1‐(benzyloxy)‐2,9,10‐trimethoxy‐6‐(methylsulfonyl)‐5,6,6a,7‐tetrahydro‐4H‐dibenzo[de,g]quinoline were

  为了探索紫花碱生物碱的潜力，提出了一系列新的功能化的紫花碱类似物，它们在A环的C1 / C2处带有烷氧基（OCH 3，OC 2 H 5，OC 3 H 7）官能团和一个酰基（COCH 3和COPh）或苯磺酰基（SO 2 P h和SO 2 C ^ 6 ħ 4 -3-CH 3）合成了Aporphine支架B环N6位的官能团，并评估了其对花生四烯酸（AA）诱导的抗血小板凝集抑制活性和2,2-二苯基-1-picylhydrazyl（DPPH）自由基清除抗氧化活性的作用，分别以乙酰水杨酸和抗坏血酸为标准。与AA诱导的血小板凝集抑制活性结果相关的初步构效关系表明，阿朴啡类似物1 [[1,2,9,10-四甲氧基-6 a，7-二氢-4 H-二苯并[ de，g ]]喹啉-6-（5 ħ） -基]乙酮和1- [2-（苄氧基）-1,9,10三甲氧基-6-一个，7-二氢-4- ħ -二苯并[de，g ]喹啉-6（5
• Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
  申请人：——

  公开号：US20040138249A1

  公开（公告）日：2004-07-15

  The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.

  本发明涉及吡咯并[2.1-a]二氢异喹啉，它们是磷酸二酯酶10a的抑制剂，可用于抗击癌症。
• Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α_1A-Adrenoceptor Antagonists
  作者：Diliang Guo、Jing Li、Henry Lin、Yu Zhou、Ying Chen、Fei Zhao、Haifeng Sun、Dan Zhang、Honglin Li、Brian K. Shoichet、Lei Shan、Weidong Zhang、Xin Xie、Hualiang Jiang、Hong Liu

  DOI：10.1021/acs.jmedchem.6b01217

  日期：2016.10.27

  A novel series of tetrahydroprotoberberine derivatives (THPBs) were designed, synthesized, and evaluated as selective α1A-adrenergic receptors (AR) antagonists for the treatment of benign prostatic hyperplasia. On the basis of the pharmacophore model of the marketed drug silodosin, THPBs were modified by introducing an indole segment into their core scaffolds. In calcium assays, 7 out of 32 compounds

  一种新型系列tetrahydroprotoberberine衍生物（THPBs）的设计，合成和评价为选择性α 1A肾上腺素能受体（AR）拮抗剂用于良性前列腺增生的治疗。根据市售的药物西洛多辛的药效团模型，通过将吲哚片段引入其核心支架来修饰THPB。在钙化验中，32种化合物中有7种对α1A -ARs表现出优异的拮抗活性，IC 50小于250 nM。其中，化合物（S）-27具有最强的生物活性。其对α1A -AR的IC 50为12.8±2.2 nM，是对α1A -AR的781和20倍。1B -和α 1D -AR，分别。在使用离体大鼠组织的功能测定中，化合物（S）-27有效抑制去甲肾上腺素引起的尿道平滑肌收缩（IC 50 = 0.5±0.3 nM），而没有抑制主动脉收缩（IC 50 > 1000 nM），表现出更好的效果。组织选择性优于市售药物西洛多辛。初步安全性研究（急性毒性和hERG抑制作用）
• Metal‐Free Selective and Diverse Synthesis of Three Distinct Sets of Isoindolinones from 2‐Alkynylbenzoic Acids and Amines
  作者：Xiuwen Jia、Pinyi Li、Xiaoning Zhang、Siyu Liu、Xingzi Shi、Wenbo Ma、Hongbo Dong、Yangbin Lu、Hangcheng Ni、Fei Zhao

  DOI：10.1002/ejoc.202001413

  日期：2020.12.20

  The metal‐free selective and diverse synthesis of three distinct sets of isoindolinones from 2‐alkynylbenzoic acids and amines in a controlled manner is reported. This process features metal free, readily available starting materials, broad substrate scope, excellent selectivity, good to high yields, good functional group tolerance, simple operation, high bond‐forming efficiency, and step economy.

  据报道，从2-炔基苯甲酸和胺类中以受控方式无选择地合成了三套不同的异吲哚啉酮。该工艺的特点是无金属，易于获得的起始原料，广泛的底物范围，优异的选择性，良好的高产率，良好的官能团耐受性，简单的操作，较高的键形成效率和步骤经济性。